0000899243-19-019138.txt : 20190703
0000899243-19-019138.hdr.sgml : 20190703
20190703161237
ACCESSION NUMBER: 0000899243-19-019138
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190701
FILED AS OF DATE: 20190703
DATE AS OF CHANGE: 20190703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOMCY CHARLES J
CENTRAL INDEX KEY: 0001192591
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 19942024
MAIL ADDRESS:
STREET 1: PORTOLA PHARMACEUTICALS, INC.
STREET 2: 270 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-07-01
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001192591
HOMCY CHARLES J
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
1
1
0
0
Chairman of Pharmaceuticals
Common Stock
2019-07-01
4
M
0
47165
A
47165
D
Common Stock
2019-07-01
4
M
0
132317
A
179482
D
Common Stock
2019-07-01
4
M
0
66729
A
246211
D
Common Stock
2019-07-01
4
M
0
406723
A
652934
D
Common Stock
2019-07-01
4
M
0
418016
A
1070950
D
Common Stock
2019-07-01
4
M
0
290476
A
1361426
D
Common Units
2019-07-01
4
M
0
47165
0.00
D
Common Stock
47165
0
D
Common Units
2019-07-01
4
M
0
132317
0.00
D
Common Stock
132317
0
D
Series B Units
2019-07-01
4
M
0
66729
0.00
D
Common Stock
66729
0
D
Management Incentive Units
2019-07-01
4
M
0
406723
0.00
D
Common Stock
406723
0
D
Management Incentive Units
2019-07-01
4
M
0
418016
0.00
D
Common Stock
418016
0
D
Management Incentive Units
2019-07-01
4
M
0
290476
0.00
D
Common Stock
290476
0
D
Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.
Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person.
Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.
Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person.
Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.
Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.
Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date.
Ralph Scarborough, as Attorney-in-fact
2019-07-03